Scholarlink

Background &amp; aim <p>Pentraxin 3 (PTX3) is an immunomodulatory molecule involved in inflammation and ovarian physiology. However, its circulating levels in polycystic ovary syndrome (PCOS) remain uncertain due to inconsistent findings. This meta-analysis aimed to clarify the association between PTX3 levels and PCOS.</p> Methods <p>A systematic search of PubMed, Embase, Scopus, Web of Science, CNKI, and Google Scholar was conducted up to April 2025 without language restrictions. Observational studies comparing circulating PTX3 levels between patients with PCOS and healthy controls were included. Effect sizes were calculated as standardized mean differences (SMDs) with 95% confidence intervals (CIs) using a random-effects model.</p> Results <p>Nineteen studies (25 datasets) involving 1,230 women with PCOS and 1,179 controls were included. Pooled analysis showed significantly higher PTX3 levels in PCOS compared with controls (SMD = 0.993; 95% CI: 0.076 to 1.909; <i>p</i> = 0.034). In subgroup analysis by BMI, the most pronounced elevation in PTX3 concentrations was observed in women with a BMI between 25 and 30&#xa0;kg/m² (SMD = 2.102; <i>p</i> = 0.008). Meta-regression analysis also identified age (β = 0.37, <i>p</i> = 0.026) as a positive and luteinizing hormone levels (β = − 0.33, <i>p</i> = 0.028) as a negative moderator of PTX3 concentrations.</p> Conclusions <p>The observed increase in PTX3 concentrations in PCOS supports its role as a candidate biomarker for disease identification and monitoring. Future studies should clarify its relationship with infertility status, explore its role across different PCOS phenotypes, and address methodological heterogeneity to refine its clinical utility.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pentraxin 3 levels in polycystic ovary syndrome: a meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月9日

查看全文
  • Reza Mohammadpour Fard,
  • Mohadese Nadi,
  • Zahra Mansouri,
  • Razieh Kazemzadeh,
  • Vahid Radmehr,
  • Mostafa Hosseinpour,
  • Tannaz Sakhavarz,
  • Seyed Sobhan Bahreiny

摘要

Background & aim

Pentraxin 3 (PTX3) is an immunomodulatory molecule involved in inflammation and ovarian physiology. However, its circulating levels in polycystic ovary syndrome (PCOS) remain uncertain due to inconsistent findings. This meta-analysis aimed to clarify the association between PTX3 levels and PCOS.

Methods

A systematic search of PubMed, Embase, Scopus, Web of Science, CNKI, and Google Scholar was conducted up to April 2025 without language restrictions. Observational studies comparing circulating PTX3 levels between patients with PCOS and healthy controls were included. Effect sizes were calculated as standardized mean differences (SMDs) with 95% confidence intervals (CIs) using a random-effects model.

Results

Nineteen studies (25 datasets) involving 1,230 women with PCOS and 1,179 controls were included. Pooled analysis showed significantly higher PTX3 levels in PCOS compared with controls (SMD = 0.993; 95% CI: 0.076 to 1.909; p = 0.034). In subgroup analysis by BMI, the most pronounced elevation in PTX3 concentrations was observed in women with a BMI between 25 and 30 kg/m² (SMD = 2.102; p = 0.008). Meta-regression analysis also identified age (β = 0.37, p = 0.026) as a positive and luteinizing hormone levels (β = − 0.33, p = 0.028) as a negative moderator of PTX3 concentrations.

Conclusions

The observed increase in PTX3 concentrations in PCOS supports its role as a candidate biomarker for disease identification and monitoring. Future studies should clarify its relationship with infertility status, explore its role across different PCOS phenotypes, and address methodological heterogeneity to refine its clinical utility.